MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress

• DOI: 10.1016/j.tranon.2021.101167
• Publication Date: 2021-07-17T05:14:56Z
• Authors: Jinwen Shi; Xiaofeng Zhang; Jin'e Li; Wenwen Huang; Yini Wang; Yi Wang; Jun Qin
• Keywords: 0301 basic medicine; 03 medical and health sciences; Olaparib; MTA2; Replication stress; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; Replication origins; Gastric cancer; RC254-282; Original Research; 3. Good health

Poly (ADP-ribose) polymerase (PARP) inhibitor olaparib selectively kills cancer cells with BRCA-deficiency and is approved for BRCA-mutated breast, ovarian and pancreatic cancers by FDA. However, phase III study of olaparib failed to show a significant improvement in overall survival in patients with gastric cancer (GC). To discover an effective biomarker for GC patient-selection in olaparib treatment, we analyzed proteomic profiling of 12 GC cell lines. MTA2 was identified to confer sensitivity to olaparib by aggravating olaparib-induced replication stress in cancer cells. Mechanistically, we applied Cleavage Under Targets and Tagmentation assay to find that MTA2 proteins preferentially bind regions of replication origin-associated DNA sequences, which could be enhanced by olaparib treatment. Furthermore, MTA2 was validated here to render cancer cells susceptible to combination of olaparib with ATR inhibitor AZD6738. In general, our study identified MTA2 as a potential biomarker for olaparib sensitivity by aggravating olaparib-induced replication stress.